March 6, 2023: We strongly support the US Preventive Services Task Force draft recommendations that all asymptomatic pregnant women be screened for high blood pressure throughout pregnancy. We appreciate the agency considering how screening will help prevent medical problems for mothers and babies that could be caused by hypertensive disorders of pregnancy.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Meeting of Patient, Consumer, and Public Health Coalition with Commissioner Califf and Key FDA Officials
March 1, 2023: As a leader of the Patient, Consumer, and Public Health Coalition, the National Center for Health Research scheduled a meeting at the FDA with Commissioner Califf and other key FDA officials to discuss accelerated approval, lab developed diagnostic tests, and improvements to FDA Advisory Committees.
Read More »Patient, Consumer, and Public Health Coalition Letter to Congress on CMS Limited Coverage for Newly Approved Alzheimer’s Drugs
February 27, 2023: NCHR urges Congress to support the decision by the Centers for
Medicare and Medicaid Services (CMS) to limit the coverage of newly approved Alzheimer’s
drugs until the treatments have been shown to have a meaningful, clinical benefit that outweighs
the risks for the Medicare population.
NCHR Comments on FDA update to “healthy” food label criteria
NCHR supports FDA’s updated criteria for the “healthy” food label focused on foods with high nutritional value and healthy eating patterns, rather than specific nutrients. However, we urge the agency to ensure the “healthy” label isn’t on foods that are highly processed, contain artificial sweeteners or are high in saturated fats. The revised definition will help consumers make informed food choices that will benefit their health.
Read More »Testimony of Dr. Diana Zuckerman before the House of Delegates Environment & Transportation Committee For HB 299
February 15, 2023: NCHR testified before the Maryland House Environment Committee to support HB299, which would require transparency about the use and disposal of artificial turf and infill. That will enable communities to make informed decisions about the environmental and health impact of these materials.
Read More »